Moral Small News Today

Somerset, N.J. (PRWEB) March 30, 2023 -- The Catalent Applied Drug Delivery Institute, which was established as a cross-industry consortium to accelerate the

Mali: Pravda je pobedila, želim da moja deca znaju da nisam plagijator 19:44 Ministar finansija Siniša Mali oglasio se nakon što je Upravni sud poništio rešenje Odbora za profesionalnu etiku Univerziteta u Beogradu da mu se zbog plagijata ne prizna doktorat. Komentari 24 Nadaj se da neće saznati šta si sve drugo. Ona ministarka iz Nemacke Luda neka zena, brze bolje dala ostavku na poziciju kad su joj ponistili diplomu, e svasta i sa tim zapadom. Ljudi lazi Kao prvo Veliki mali plagijat...

Dec 28, 2020 8:41am Following a trial error and a data release that only raised more questions, AstraZeneca now has a "winning formula" for its COVID-19 vaccine, CEO Pascal Soriot told the Sunday Times. (AstraZeneca) AstraZenecas early COVID-19 trial data not only fell short of Pfizer and Modernas expectation-beating stats, they raised a host of questions thanks to a dosing error in one group of trial patients. But with the U.K. suffering under a new viral strain and a quick vaccine approval e...

Dec 23, 2020 9:47am Takeda is selling five cardiovascular and metabolism drugs in the Chinese market to local company Hasten Biopharmaceutic for $322 million. (Takeda) Takeda has already exceeded the product sell-off goal it set alongside its Shire merger, but the Japanese pharma shows no sign of slowing down. After making several geography-specific divestitures in different regions of the world, Takeda has turned to China. The company said Monday it agreed to offload some cardiovascular and me...

Dec 22, 2020 7:59am The European approval for ViiV Healthcares HIV treatment Vocabria comes nine months after Health Canada became the first regulator to clear the drug. (artJazz/iStock/Getty Images Plus/Getty Images)(Photo by artJazz/iStock/Getty Images Plus/Getty Images) ViiV Healthcare has won approval for its long-acting injectable HIV treatment Vocabria in Europe. The authorization clears ViiV to sell a drug that could reduce the number of doses patients need to take a year from 365 to six...

Dec 22, 2020 3:00am Drug manufacturers are looking for a more local future for production post-COVID-19. (Pixabay)(Monica Alleven/Fierce Wireless) With the COVID-19 pandemic perhaps entering its final phase as the first wave of vaccines approaches the market, one question left unanswered is the future of "onshoring" drug manufacturing—an initiative that reached fever pitch in 2019 as nationwide lockdowns and geopolitical tension cast a spotlight on the global supply chain. In 2019, congressio...

RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies) Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site. Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North C...

Dec 22, 2020 9:15am Big name pharmas, budding biopharmas and research institutions the world over are plugging away on the next generation of drugs and vaccines against the COVID-19 pandemic. (Bill Oxford/Getty Images) As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020—and theyre looking at new formulations and delivery methods to bring vaccines and therapies to more people around the world.  Can follow-up sh...

Dec 22, 2020 9:00am Drugmakers believe COVID-19 may change the ways of working for good, even after the pandemic eases. (Getty Images) As COVID-19 vaccines are rolling out in different parts of the world, perhaps it’s finally time to talk about life after the pandemic. But biopharma companies believe it’s too early to put a specific timeline on turning that page now. Despite all the unknowns, though, one thing seems certain: How drugmakers conduct their business will change. After navigat...

Dec 21, 2020 11:00am WuXi Biologics will pay Bayer €150 million to take charge at the companys drug product manufacturing plant in Wuppertal, Germany—one of two German plants WuXi picked up from the drugmaker this year. (Bayer) Shanghais WuXi Biologics is ending the year how it started: with plans to take charge at a Bayer facility in Germany. The companys latest site acquisition follows deals for three U.S. facilities this year, part of WuXi Bios gung-ho expansion efforts outside of C...